Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT04471870
ARCANGELO (itAlian pRospective Study on CANGrELOr)
1,005 Enrollment(s)
30 Study location(s)
OBSERVATIONAL (None)
Acute Coronary Syndrome
NOT_YET_RECRUITING
NCT07416253
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
68 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
RECRUITING
NCT06467357
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
620 Enrollment(s)
262 Study location(s)
INTERVENTIONAL (PHASE3)
Biliary Tract Cancer
RECRUITING
NCT06494111
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
295 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Lymphedema


Fibrosis
WITHDRAWN
NCT06585969
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic Breast Cancer


ER-positive Breast Cancer


Luminal B


Her2 Enriched


Basal Like
RECRUITING
NCT05993234
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
257 Enrollment(s)
76 Study location(s)
OBSERVATIONAL (None)
HER2-positive Advanced Gastric Cancer


HER2-positive Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT05945732
DESTINY Breast Respond HER2-low Europe
1,155 Enrollment(s)
211 Study location(s)
OBSERVATIONAL (None)
Unresectable Breast Cancer


Metastatic Breast Cancer


HER2-low Expressing Breast Cancer
RECRUITING
NCT06769490
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
44 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Acute Myeloid Leukemia